PCM
RPRX icon

Polymer Capital Management’s Royalty Pharma RPRX Stock Holding History

Polymer Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$536K Buy
+9,552
New +$497K 0.07% 349
2026
Q1 		– Sell
-17,799
Closed -$688K – 996
2025
Q4 		$688K Buy
+17,799
New +$679K 0.07% 394

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Polymer Capital Management's RPRX Position: Q2 2026 in Review

Polymer Capital Management opened a new position in Royalty Pharma (RPRX) in Q2 2026: 9,552 shares worth $536K. The stake represents 0.07% of the portfolio and ranks #349 among its holdings. This is a return to the name: Polymer Capital Management previously reported a position in RPRX as recently as Q4 2025.

Polymer Capital Management first reported a position in RPRX in Q4 2025 and has held it in 2 quarters since. The position peaked at $688K in Q4 2025. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Polymer Capital Management held 9,552 shares of Royalty Pharma worth $536K as of Q2 2026.
  • Royalty Pharma was a new Polymer Capital Management position in Q2 2026.
  • Royalty Pharma made up 0.07% of Polymer Capital Management's portfolio in Q2 2026, its #349 holding.
  • Polymer Capital Management first reported a position in Royalty Pharma in Q4 2025 and has held it in 2 quarters since.
  • Polymer Capital Management's Royalty Pharma position peaked at $688K in Q4 2025.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Polymer Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.